All In Biotech

Drug Trial Radar · NCT02676089

TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)

A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 3-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 200/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) ALONE OR ON TOP OF OPEN-LABEL TIOTROPIUM 2.5 µg RESPIMAT® IN PATIENTS WITH ASTHMA UNCONTROLLED ON HIGH DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,437 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,437

Actual

Start

Apr 6, 2016

Primary completion

May 28, 2018

Study completion May 28, 2018

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Feb 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate) in patients with uncontrolled asthma under medium doses of inhaled corticosteroid/long-acting β2-adrenergic receptor agonists (ICS/LABA), in patients with uncontrolled asthma who received medium doses of ICS/LABA. The treatments tested the improvement of the forced expiratory volume in the 1st second (FEV1) and the reduction of moderate and severe asthma exacerbations rate.

Conditions

  • Asthma

Interventions

  • CHF 5993 200/6/12.5 µgDrug

  • CHF 1535 200/6 µgDrug

  • CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26Time frame: Week 0 (pre-treatment, baseline) to Week 26.
  2. 2_Moderate and Severe Asthma Exacerbation Rate Over the 52-Week Treatment PeriodTime frame: Week 0 (pre-treatment, baseline) to Week 52.

Locations

244 sites in 17 countries. Site status is shown where the registry gives one.

  • Chiesi Clinical Trial Site 432702

    Buenos Aires, Argentina

  • Chiesi Clinical Trial Site 432704

    CABA, Argentina

  • Chiesi Clinical Trial Site 432705

    Mar del Plata, Argentina

  • Chiesi Clinical Trial Site 432701

    Quilmes, Argentina

  • Chiesi Clinical Trial Site 432703

    San Miguel de Tucumán, Argentina

  • Chiesi Clinical Trial Site 432706

    San Miguel de Tucumán, Argentina

  • Chiesi Clinical Trial Site 112703

    Homyel, Belarus

  • Chiesi Clinical Trial Site 112704

    Homyel, Belarus

  • Chiesi Clinical Trial Site 112701

    Minsk, Belarus

  • Chiesi Clinical Trial Site 112702

    Minsk, Belarus

  • Chiesi Clinical Trial Site 112705

    Minsk, Belarus

  • Chiesi Clinical Trial Site 100707

    Blagoevgrad, Bulgaria

  • Chiesi Clinical Trial Site 100720

    Burgas, Bulgaria

  • Chiesi Clinical Trial Site 100718

    Gabrovo, Bulgaria

  • Chiesi Clinical Trial Site 100713

    Haskovo, Bulgaria

  • Chiesi Clinical Trial Site 100722

    Montana, Bulgaria

  • Chiesi Clinical Trial Site 100702

    Pleven, Bulgaria

  • Chiesi Clinical Trial Site 100705

    Plovdiv, Bulgaria

  • Chiesi Clinical Trial Site 100708

    Plovdiv, Bulgaria

  • Chiesi Clinical Trial Site 100715

    Plovdiv, Bulgaria

  • Chiesi Clinical Trial Site 100716

    Rousse, Bulgaria

  • Chiesi Clinical Trial Site 100701

    Sofia, Bulgaria

  • Chiesi Clinical Trial Site 100703

    Sofia, Bulgaria

  • Chiesi Clinical Trial Site 100704

    Sofia, Bulgaria

  • Chiesi Clinical Trial Site 100709

    Sofia, Bulgaria

  • Chiesi Clinical Trial Site 100719

    Sofia, Bulgaria

  • Chiesi Clinical Trial Site 100706

    Stara Zagora, Bulgaria

  • Chiesi Clinical Trial Site 100712

    Stara Zagora, Bulgaria

  • Chiesi Clinical Trial Site 100710

    Varna, Bulgaria

  • Chiesi Clinical Trial Site 100711

    Vidin, Bulgaria

  • Chiesi Clinical Trial Site 100721

    Vidin, Bulgaria

  • Chiesi Clinical Trial Site 203711

    Blansko, Czechia

  • Chiesi Clinical Trial Site 203702

    Brandýs nad Labem, Czechia

  • Chiesi Clinical Trial Site 203708

    Brno, Czechia

  • Chiesi Clinical Trial Site 203707

    Jindřichův Hradec, Czechia

  • Chiesi Clinical Trial Site 203705

    Kralupy nad Vltavou, Czechia

  • Chiesi Clinical Trial Site 203709

    Miroslav, Czechia

  • Chiesi Clinical Trial Site 203704

    Opava, Czechia

  • Chiesi Clinical Trial Site 203701

    Prague, Czechia

  • Chiesi Clinical Trial Site 203703

    Prague, Czechia

Showing 40 of 244 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.